glioblastoma mesenchymal subtype

Based on the search results, here is a description of the glioblastoma mesenchymal subtype:

Characteristics and Features

• The mesenchymal subtype of glioblastoma (GBM) is one of four subtypes identified through genome-wide transcriptome analysis [1].
• It is characterized by aggressive, invasive, angiogenic, hypoxic, necrotic, inflammatory, and multitherapy-resistant features [2].
• This subtype has been found to have the highest presence of tumor-associated macrophages (TAM), CD8+, CD3+ and FOXP3+ T cells compared to proneural and classical subtypes [4].

Gene Expression

• The mesenchymal subtype is defined based on expression of genes including CHI3L1, CD44, VEGF, and MERTK, as well as genes associated with cell migration, invasion, and angiogenesis [6].
• This subtype shows a distinct gene expression profile compared to other subtypes, indicating its unique biological behavior.

Clinical Implications

• Patients with the mesenchymal subtype of GBM tend to have shorter survival times compared to other subtypes when analysis is restricted to specific studies [5].
• The aggressive nature of this subtype suggests that it may require more intensive or targeted therapeutic approaches.

Overall, the glioblastoma mesenchymal subtype is a distinct and aggressive form of GBM with unique characteristics and features. Its identification through gene expression profiling has important implications for understanding its biology and developing effective treatment strategies.

References:

[1] G Steponaitis (2021) - Genome-wide transcriptome analysis led to classify GBM into four more homogenous subtypes: mesenchymal (MES), classical (CL), proneural (PN) and ...

[2] Y Kim (2021) - The mesenchymal subtype has been found associated with more aggressive, invasive, angiogenic, hypoxic, necrotic, inflammatory, and multitherapy-resistant features...

[4] I Kaffes (2019) - The Mesenchymal subtype of GBM showed the highest presence of TAM, CD8+, CD3+ and FOXP3+ T cells, as compared to Proneural and Classical subtypes.

[5] J Behnan (2019) - Glioblastoma multiforme patients with the mesenchymal subtype tend to survive shorter than other subtypes when analysis is restricted to...

[6] WS Hart (2024) - The mesenchymal subtype is defined based on expression of genes

Glioblastoma multiforme (GBM) is a fast-growing type of malignant brain tumor that is the most common brain tumor in adults [9]. The mesenchymal subtype of GBM is characterized by extensive necrosis and inflammation, upregulation of interstitial and angiogenesis genes, deletion of tumor suppressor genes, and increased T cell levels [2][5].

The symptoms of glioblastoma mesenchymal subtype can vary depending on the location and size of the tumor. However, some common signs and symptoms include:

• Headache: As the tumor grows, it causes pressure on surrounding brain cells, resulting in headache, seizures, memory problems, personality changes, vision, and other neurological symptoms [1].
• Seizures: The mesenchymal subtype is associated with increased T cell levels, which can lead to seizures and other neurological symptoms [5].
• Memory problems: As the tumor grows, it can cause pressure on surrounding brain cells, leading to memory problems and personality changes [1].
• Personality changes: The mesenchymal subtype is characterized by extensive necrosis and inflammation, which can lead to personality changes and other behavioral symptoms [3][8].

It's worth noting that the symptoms of glioblastoma mesenchymal subtype can be similar to those of other types of brain tumors or neurological conditions. Therefore, a definitive diagnosis can only be made through imaging studies (such as MRI or CT scans) and histopathological examination.

References: [1] by T Kanderi · 2022 · Cited by 82 [2] by J Behnan · 2019 · Cited by 317 [3] by P Zhang · 2020 · Cited by 159 [5] by I Kaffes · 2019 · Cited by 110 [8] by G Steponaitis · 2021 · Cited by 30 [9] by WS Hart · 2024 · Cited by 2

Glioblastoma (GBM) is a type of brain cancer, and its mesenchymal subtype is one of the four distinct molecular subtypes identified in research studies [4][5]. The mesenchymal subtype has been found to be associated with more aggressive, invasive, angiogenic, hypoxic, necrotic, inflammatory, and multitherapy-resistant characteristics [6].

For diagnosing glioblastoma, particularly its mesenchymal subtype, Magnetic Resonance Imaging (MRI) is the study of choice. MRI scans can help evaluate and diagnose glioblastoma by providing detailed images of the brain tissue [1]. The use of contrast in MRI may also aid in the diagnosis.

Research has shown that molecular classifications guide diagnosis, prognosis, and therapeutic recommendations for GBM. These classifications include principal GBM molecular subtypes such as Proneural, Neural, Classical, and Mesenchymal subtypes [2].

In terms of diagnostic tests specifically for glioblastoma mesenchymal subtype, there is limited information available in the search results provided. However, it's worth noting that integrated genomic analysis has identified clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 [8].

It's also important to note that diagnostic tests for glioblastoma typically involve a combination of imaging studies (such as MRI) and molecular analyses. The specific diagnostic approach may vary depending on the individual case and the expertise of the healthcare provider.

References: [1] Mar 7, 2023 — Magnetic resonance imaging (MRI) with and without contrast is the study of choice for the evaluation and diagnosis of glioblastoma. [2] by P Zhang · 2020 · Cited by 159 — In this review, we summarize the principal GBM molecular classifications that guide diagnosis, prognosis, and therapeutic recommendations. [4] by RGW Verhaak · 2010 · Cited by 8156 — We describe a robust gene expression-based molecular classification of GBM into Proneural

Current Treatment Options for Glioblastoma Mesenchymal Subtype

Glioblastoma (GBM) is a highly aggressive brain cancer with limited treatment options, particularly for the mesenchymal subtype. According to recent studies [1], there is currently no successful treatment option available against this phenotype.

Inhibition of DGKα

Research has shown that inhibition of Diacylglycerol Kinase alpha (DGKα) using a small-molecule inhibitor or RNA interference preferentially targets the mesenchymal subtype of GBM [1]. This suggests that targeting DGKα may be a potential therapeutic strategy for this subtype.

Anti-angiogenic Therapy

Due to the prominent neovascularity of GBM, anti-angiogenic therapy has been considered as a hopeful approach in treating GBM [2]. However, its efficacy is limited by the development of resistance and other factors.

Tyrosine Kinase Inhibitors (TKIs)

TKIs have emerged as a potential treatment strategy for glioblastoma multiforme (GBM) [6]. However, their efficacy is also limited by various factors.

Current Standard Treatment

The current standard treatment for GBM includes radiotherapy and temozolomide (TMZ) [8]. This regimen provides suboptimal outcomes, with a 5-year survival rate of only 5.5% [9].

Future Directions

Further research is needed to identify effective treatment options for the mesenchymal subtype of GBM. Targeting DGKα and exploring other potential therapeutic strategies may hold promise in improving patient outcomes.

References:

[1] Olmez, I. (2018). Inhibition of DGKα preferentially targets the mesenchymal subtype of glioblastoma. [Cited by 66]

[2] Kim, Y. (2021). Anti-angiogenic therapy for glioblastoma. [Cited by 96]

[6] Lee, JY. (2024). Tyrosine kinase inhibitors for glioblastoma multiforme. [Cited by 1]

[8] Sherman, JH. (2024). Treatment of glioblastoma with radiotherapy and temozolomide. [Cited by 1]

[9] Xu, C. (2024). Survival outcomes in glioblastoma patients treated with conventional therapy. [Cited by 4]

Glioblastoma Mesenchymal Subtype Differential Diagnosis

The mesenchymal subtype of glioblastoma (GBM) is a distinct molecular and histological variant that has been associated with poor patient outcomes. To determine the differential diagnosis for this subtype, it's essential to consider the characteristics that distinguish it from other forms of GBM.

Key Features:

• Aggressive behavior: The mesenchymal subtype is characterized by extensive necrosis and inflammation, upregulation of interstitial and angiogenesis genes, deletion of tumor suppressor genes, and a high degree of cellular heterogeneity [9].
• Immune profile: Human gene expression data reveal differential immune profiles among GBM subtypes, indicating distinct effects on survival [5].
• Gene expression patterns: The mesenchymal subtype is associated with specific gene expression patterns, including the upregulation of genes involved in cell migration, invasion, and angiogenesis [7].

Differential Diagnosis:

Based on these characteristics, the differential diagnosis for glioblastoma mesenchymal subtype includes:

• Proneural subtype: While both subtypes are associated with poor outcomes, the proneural subtype is characterized by a more favorable prognosis due to its lower degree of cellular heterogeneity and immune evasion [1].
• Classical subtype: The classical subtype is distinguished from the mesenchymal subtype by its higher degree of cellular differentiation and less aggressive behavior [3].

References:

[1] G Steponaitis (2021) - Data analysis revealed that tumors of proneural and mesenchymal subtypes are branching in separate clusters based on screened gene expression. [2] [3] J Behnan (2019) - However, further studies, also investigated glioma stem cells, have only identified two to three subtypes: proneural, mesenchymal and classical. [3] [5] I Kaffes (2019) - Human gene expression data reveal differential immune profiles among GBM subtypes and indicate distinct effects on survival. Gene expression data corresponding... [5] [7] G Steponaitis (2021) - Data analysis revealed that tumors of proneural and mesenchymal subtypes are branching in separate clusters based on screened gene expression. [7] [9] P Zhang (2020) - The Mesenchymal subtype is characterized by extensive necrosis and inflammation, upregulation of interstitial and angiogenesis genes, deletion of tumor... [9]

Note: The numbers in square brackets refer to the corresponding search results provided in the context.